How to Identify Best-Fit Investors at Partnering Events 

By Sougato Das, President and COO, LSN

Sougato-DasPartnering conferences are a great place to meet investors, in-licensors and strategic partners. These events tend to be segmented in the following ways:

1) Focus: General, Licensing/BD or Investment

2) Modality: Biotech, Device/Diagnostics, Digital Health

3) Therapeutic area: General or Therapeutic area-specific

4) Stage: General or Early Stage

While it seems obvious, it is critical to align your events (and your limited time and budget) with your company objectives. In my experience at dozens of different partnering conference, I’ve found that each of the above are largely binary. For example, while a Licensing/BD conference will have some investors attending, you’ll have many more meetings with investors at a investment-focused meeting. And vice-versa. Additionally, an interesting pattern that I’ve noticed is when it comes to stage, a partnering event that has a general focus tends to skew late-stage (clinical or later, with lots of players looking for phase 3 or commercial assets). This leaves companies with preclinical or early clinical assets scrambling to identify and meet the relatively few investors who are interested in early-stage companies.

Since partnering conferences allow for a limited number of outgoing meeting requests that can be in the ‘requested’ state, it’s important for you to be able to identify the attending investors that are a good fit for your company. This is complicated by the fact that investors typically don’t do a stellar job populating their profile with information that makes their remit clear. While it may be tempting to use the filters provided by the partnering system to identify best-fit investors, this ONLY works if every investor profile is consistently populated. Why? Because blank values are not returned in filtered searches. What does that mean? That means that if you use the filters in the partnering system to look for those who invest in oncology, and there are some oncology investors who have not filled out their therapeutic area field in their profile, those investors will not be returned in the results. Some partnering conference providers, such as RESI, prevent this issue by having the staff populate the investor profiles on behalf of the investors, ensuring that all profiles are complete and searchable.

All that said, what do you need to look for to find the investors that fit your company best? The most important criteria (that you probably know already if you’ve done any investor outreach) is stage. “Too early” is a response that every pre-clinical and phase 1 company has heard a million times. At RESI it’s easy. You can filter accurately on stage. But at other conferences that depend on the investor to self-populate their profile, you’ll have to read the profile carefully and visit the website. If it doesn’t say explicitly, then look at the portfolio companies.

The next aspect is the assets under management and the check size range. This kind of information not only shows if the investor is appropriate for the amount you’re raising, but also shows if the investor is indeed an investor and not a financial consultancy or investment bank (in some conferences, such entities end up being classified as investors).

Next, and as alluded to above, is the therapeutic area focus. While many investors go across therapeutic areas, some focus on only one or a few.

Next is the modality. Of course if you’re a med tech investor you don’t want to target a biotech-only investor. Within biotech, there are some investors that only do advanced therapies and some who do everything except advanced therapies. Etc.

Next there is the geographic focus. Some investors target specific geographies.

Finally, there is the investor type or model. Not all investors are equity investors. Some are debt, some royalty, some are venture builders, some are CROs that provide services for equity, etc.

If you have access, looking up the investor in Life Science Nation’s investor database will return all the details you need with regard to the above. Other databases have information on investments a given investor made, which provides some insight. By ensuring the investor you send a meeting request to is actually suitable for your company, you’ll maximize your ROI and, with any luck, extend your cash runway.

Register for RESI San Diego

Innovator’s Pitch Challenge: Where Deals Start

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

At most conferences, startup pitch competitions are treated as side programming. Founders present a deck, judges select winners, applause follows, and the event moves on.

At RESI San Diego, the Innovator’s Pitch Challenge (IPC) is designed differently.

The IPC is not simply about winning a competition. It is designed to help early-stage life science companies generate investor attention, create business development momentum, and accelerate conversations that continue long after the presentation ends.

For many companies, that interaction becomes the most valuable part of the experience.

“The discussions also felt far more relationship-driven than transactional,” said Sian Farrell, CEO of StimOxyGen. “Conversations extended beyond the pitch itself and focused on clinical strategy, regulatory pathways, commercialization, and long-term value creation.”

Unlike standalone pitch competitions, the IPC is integrated directly into the larger RESI partnering ecosystem. Participating companies also receive partnering access, poster presentation visibility, and exposure throughout the conference environment, creating multiple opportunities for follow-up interaction.

“The combination of the presentation and the partnering platform made a significant difference,” said Bram de Moor, CEO of You2Yourself. “RESI brought us into direct contact with European and transatlantic life science investors who specifically seek early-stage diagnostic and biomarker companies — an audience difficult to reach through cold outreach.”

The IPC also introduces an interactive audience component through “RESI cash,” distributed to attendees during registration. Participants allocate their RESI cash to the companies they believe demonstrate the strongest potential, creating additional visibility and engagement throughout the event.

For founders navigating today’s capital environment, opportunities that combine exposure with concentrated investor access are increasingly valuable.

As fundraising conditions continue to demand stronger differentiation and clearer commercialization pathways, platforms that help companies sharpen messaging and generate high-quality investor interaction have become increasingly important.

At RESI, the IPC is intended to serve exactly that purpose.

Selected companies receive:

  • Two 5-day RESI registrations
  • A six-minute company presentation followed by seven minutes of investor Q&A
  • Poster presentation space
  • Full partnering access
  • Exposure to investors, strategic partners, and pharma business development teams throughout Convention Week

For many founders, the IPC becomes more than a presentation opportunity. It becomes the place where investor conversations begin, strategic relationships form, and fundraising momentum accelerates.

Applications for the Innovator’s Pitch Challenge at RESI San Diego are currently open, with limited presentation slots remaining.

Apply to Pitch at RESI San Diego

Hot Investor Mandate: Healthcare Impact-Driven VC Funds Pre-Series A and Series B Technologies Improving Healthcare Access and Outcomes

A global healthcare-focused impact venture capital fund affiliated with a broader healthcare innovation platform is headquartered in Asia. The firm invests equity capital into technology-enabled healthcare companies, typically deploying investments ranging from approximately $500K to $2M. The firm targets opportunities from Pre-Series A through Series B stages and seeks companies capable of delivering both measurable healthcare impact and strong financial returns. The firm invests globally, with particular interest in solutions that can scale across domestic markets as well as other emerging healthcare markets.  

The firm focuses on technologies that improve healthcare access, outcomes, and quality of care. Core investment themes include preventive healthcare and self-care solutions, healthy aging and longevity, holistic wellness, and AI-enabled hospital technologies. The firm prioritizes scalable digital health platforms, data-driven healthcare technologies, and tech-enabled services addressing systemic healthcare challenges across provider systems, hospital infrastructure, and consumer health channels.  

From a company and management team perspective, the firm seeks teams with strong operational execution, clearly defined impact objectives, and the ability to scale across diverse healthcare environments. The firm prioritizes companies with validated technologies, credible commercial models, and realistic market adoption strategies. Beyond capital, the firm provides portfolio companies with access to strategic partnerships, healthcare providers, hospital systems, and regional expansion support across Southeast Asia and other high-growth markets. The firm is open to acting as either a lead investor or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Venture Arm of International Healthcare Company Invests in Life Science Technologies Addressing Respiratory Disease, CNS, Women’s Health 

A venture investment arm of an international healthcare and pharmaceutical organization is focused on advancing innovative patient-centered solutions. The firm invests in early-stage life sciences companies developing breakthrough therapeutics, medical devices, digital health technologies, nutraceuticals, and medical foods. The firm prioritizes opportunities aligned with key strategic healthcare areas and supports portfolio companies through industry expertise and international commercial networks.  

The firm focuses on respiratory diseases, central nervous system and neurological disorders, and women’s health. Within women’s health, areas of particular interest include urinary tract infections, vaginal infections, and related unmet healthcare needs. The firm evaluates opportunities across therapeutics, diagnostics, digital health, medical devices, nutraceuticals, and medical foods that can improve patient access, disease management, and quality of care. The firm does not invest in oncology and generally avoids technologies designed exclusively for inpatient or hospital-only environments, preferring solutions accessible in broader patient-care settings.  

In addition to early-stage investments, the firm is open to strategic collaborations with companies that already have commercialized products and are seeking international expansion opportunities. The firm leverages the broader organization’s global infrastructure and commercial presence to support geographic growth and market access.  

From a company and management team perspective, the firm seeks teams with strong scientific or clinical expertise and a clear commitment to impactful innovation. While prior industry experience is viewed positively, the firm remains open to working with promising founders and syndicate partners aligned with its strategic focus areas. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Europe-Based Life Sciences Focused VC Builds and Invests in Therapeutics Companies Across Oncology, Rare Diseases, and More

A life sciences-focused venture capital firm with offices in Europe focuses on disruptive early-stage life sciences companies and invests primarily in therapeutics. The firm is actively investing through its latest fund and has built a portfolio of multiple startups through both direct investments and company creation initiatives. The firm invests predominantly in Europe, with a strong emphasis on opportunities in Western Europe. 
 
The firm invests primarily in therapeutics and does not currently focus on medical devices, diagnostics, or digital health. The firm is modality-agnostic and evaluates a broad range of therapeutic approaches. Areas of strongest interest include oncology, immuno-oncology, rare and orphan diseases, infectious diseases, and immunology. The firm typically invests from preclinical through early clinical stages and focuses on opportunities with the potential to become first- or best-in-class therapies. 
 
From a company and management team perspective, the firm is open to working with both experienced operators and first-time entrepreneurs and has supported several companies led by first-time CEOs. The firm places strong emphasis on diversity in leadership and maintains a hands-on investment approach, actively mentoring and supporting portfolio companies. The firm is open to acting as either a lead investor or co-investor and works closely with scientific founders, academic institutions, and syndicate partners to help companies scale and mature. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Multi-Stage VC Firm With Ties to Global Financial Service Group Seeks Therapeutics and Medtech Addressing Unmet Medical Needs

A long-established venture capital firm based in Asia is affiliated with one of the world’s largest financial services groups. The firm invests across multiple sectors, including life sciences, and has the flexibility to deploy multi-million-dollar investments depending on the opportunity. The firm evaluates opportunities globally and is actively seeking new international investments. 

Within life sciences, the firm focuses on therapeutics and medical technologies that address significant unmet medical needs relevant to the firm’s domestic market. The firm is particularly interested in companies with clear partnership strategies involving pharmaceutical or healthcare organizations, including licensing, co-development, and strategic investment structures. The firm evaluates a range of therapeutic modalities including small molecules, biologics, biosimilars, and reformulated products. The firm primarily targets programs in Phase I clinical development but may also consider opportunities approaching clinical entry within approximately one year. Areas of interest include oncology, orphan diseases, and other high unmet need indications. 

From an investment structure perspective, the firm prefers to co-invest alongside established institutional investors in opportunities outside its domestic market. As a result, the firm strongly prefers companies with a credible lead investor or an existing institutional syndicate already in place. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Mastering the Hybrid Hustle: Right Partnering Strategies at Convention Week

By Caitlin Dolegowski, Program Director, LSN

Partnering conferences are a vital catalyst in an early-stage company’s journey toward securing capital and achieving milestone fundraising goals.

To help you get the absolute most bang for your buck during San Diego Convention Week, here are the top 8 strategies to maximize your ROI on the partnering meetings.

  1. Book Your Registration and Travel Early

Beyond the financial perks, registering early ensures that you are among the very first attendees to gain access to the Partnering system when it opens. In the world of fundraising, the early bird gets the open calendar slot before an investor’s schedule is completely booked.

  1. Perfect Your Partnering Profile Before Sending a Single Message

Once your partnering login hits your inbox, don’t rush straight to messaging. First, meticulously fill out your company profile, detail your tech, and upload your marketing materials (pitch deck and executive summary).

Investors will vet your profile page before hitting “Accept” on a meeting request; an incomplete profile is an automatic decline.

  1. Treat Your Meeting Requests Like a High-Value Pitch

When you begin reaching out to the hundreds of investors, your message needs to be crisp and compelling. Investors want to see specific data points right away. Ensure your meeting requests concisely address:

  • The Hook: Introduce yourself and your company.
  • The Tech: Clearly explain the product/platform.
  • The Market: What critical unmet medical need does it address?
  • The Edge: What does the competition look like, and why are you better?
  • The Traction: Major landmarks, IP status, or clinical achievements to date.
  • The Ask: Current financing needs and exactly how the capital will be used.
  1. Aggressively Fill Your Calendar

Fundraising is a numbers game. Use the partnering system’s advanced filter functions to map out investors who strictly match your company’s sector, indication, and fundraising size. Remember: Most investors will not contact you proactively. You must drive the outreach.

  1. Skip the Morning Rush: Grab Your Badge Early

Most conferences allow you to pick your event badge early. Keep an eye out for the early registration announcements. Picking up your badge a day early allows you to beat the morning lines, scope out the venue, and map your routes between partnering tables and panels so you don’t waste a single minute.

  1. There Are No Breaks in Fundraising

The in-person day in San Diego is an immersive networking marathon. Socializing over breakfast, lunch, and during the evening cocktail reception is just as critical as your scheduled partnering slots. Keep your elevator pitch polished, have your digital business cards or QR codes ready, and be prepared to network with everyone around you. You never know who you might sit next to at lunch.

  1. Be Flexible and Consider All Meeting Types

If an investor turns down a formal meeting request due to a scheduling conflict, do not give up. Use the flexibility of the multiple partnering days to find a slot. Even if a mutual window can’t be found within the conference dates, use the platform to pivot and pitch an ad-hoc meeting via Zoom or a coffee chat outside the formal boundaries.

  1. Network Peer-to-Peer

While investors are the primary target, remember the immense value of talking to fellow founders, CEOs, and service providers. Building a network of peers allows you to share fundraising intelligence, compare notes on active investors, and discover trusted vendors.

Think Big: Build a Full-Year Partnering Runway

Because fundraising is a continuous effort, looking at a single event in isolation can leave gaps in your capital pipeline. LSN hosts five RESI conferences a year globally, feeding into an internal database tracking over 10,000 early-stage life science investors across Venture Capital, Family Offices, Angels, and Corporate Venture arms.

To maintain unstoppable momentum from summer into fall, look into options like the RESI San Diego & RESI Boston Bundle, which locks in your 5-Day Hybrid passes for both the June San Diego and September Boston events. Plan your milestones around the RESI calendar, start your outreach early, and put your best foot forward this June!

Register for RESI San Diego